EE200300301A - Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid - Google Patents

Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid

Info

Publication number
EE200300301A
EE200300301A EEP200300301A EEP200300301A EE200300301A EE 200300301 A EE200300301 A EE 200300301A EE P200300301 A EEP200300301 A EE P200300301A EE P200300301 A EEP200300301 A EE P200300301A EE 200300301 A EE200300301 A EE 200300301A
Authority
EE
Estonia
Prior art keywords
antagonists
disorders
novel compounds
agonists
substituted
Prior art date
Application number
EEP200300301A
Other languages
English (en)
Estonian (et)
Inventor
J. Robichaud Albert
S. Mitchell Ian
Lee Taekyu
Chen Wenting
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of EE200300301A publication Critical patent/EE200300301A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300301A 2000-12-20 2001-12-19 Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid EE200300301A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25676500P 2000-12-20 2000-12-20
PCT/US2001/049374 WO2002059127A2 (fr) 2000-12-20 2001-12-19 Derives de pyrazinoquinoxaline substituee en tant qu'agonistes et antagonistes des recepteurs de serotonine

Publications (1)

Publication Number Publication Date
EE200300301A true EE200300301A (et) 2003-10-15

Family

ID=22973498

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300301A EE200300301A (et) 2000-12-20 2001-12-19 Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid

Country Status (23)

Country Link
US (1) US6638934B2 (fr)
EP (1) EP1345942B9 (fr)
JP (2) JP4346307B2 (fr)
KR (1) KR20030069192A (fr)
CN (1) CN1505631A (fr)
AT (1) ATE318819T1 (fr)
AU (1) AU2002248216B2 (fr)
BG (1) BG107864A (fr)
BR (1) BR0116347A (fr)
CA (1) CA2431970A1 (fr)
DE (1) DE60117617T2 (fr)
EE (1) EE200300301A (fr)
ES (1) ES2260335T3 (fr)
HU (1) HUP0303513A3 (fr)
IL (1) IL156201A0 (fr)
IS (1) IS6850A (fr)
MX (1) MXPA03005437A (fr)
NO (1) NO20032795L (fr)
PL (1) PL366060A1 (fr)
RU (1) RU2003121406A (fr)
SK (1) SK7022003A3 (fr)
WO (1) WO2002059127A2 (fr)
ZA (1) ZA200304303B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366060A1 (en) * 2000-12-20 2005-01-24 Bristol-Myers Squibb Pharma Company Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2727585A1 (fr) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited Méthode de dépistage in-vivo
EP2789338A3 (fr) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
EP2510949A4 (fr) 2009-12-11 2013-11-13 Astellas Pharma Inc Agent thérapeutique pour la fibromyalgie
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
HUT61548A (en) * 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
NZ512765A (en) * 1998-12-17 2003-10-31 Wyeth Corp 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
PL366060A1 (en) * 2000-12-20 2005-01-24 Bristol-Myers Squibb Pharma Company Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists

Also Published As

Publication number Publication date
CN1505631A (zh) 2004-06-16
RU2003121406A (ru) 2004-12-27
EP1345942B9 (fr) 2006-11-15
US20020177596A1 (en) 2002-11-28
JP4346307B2 (ja) 2009-10-21
NO20032795L (no) 2003-08-04
US6638934B2 (en) 2003-10-28
JP2009215304A (ja) 2009-09-24
DE60117617T2 (de) 2007-01-25
PL366060A1 (en) 2005-01-24
CA2431970A1 (fr) 2002-08-01
DE60117617D1 (de) 2006-04-27
ATE318819T1 (de) 2006-03-15
JP2004524298A (ja) 2004-08-12
BR0116347A (pt) 2004-07-06
KR20030069192A (ko) 2003-08-25
ES2260335T3 (es) 2006-11-01
WO2002059127A2 (fr) 2002-08-01
IL156201A0 (en) 2003-12-23
EP1345942A2 (fr) 2003-09-24
JP5117440B2 (ja) 2013-01-16
WO2002059127A3 (fr) 2002-10-03
MXPA03005437A (es) 2003-09-10
HUP0303513A3 (en) 2005-12-28
AU2002248216B2 (en) 2007-03-01
IS6850A (is) 2003-06-18
SK7022003A3 (en) 2004-08-03
NO20032795D0 (no) 2003-06-19
HUP0303513A2 (hu) 2004-01-28
EP1345942B1 (fr) 2006-03-01
ZA200304303B (en) 2004-09-02
BG107864A (bg) 2004-03-31

Similar Documents

Publication Publication Date Title
EE200300303A (et) Asendatud pürrolokinoliinid ja püridokinoliinid kui serotoniini agonistid ja antagonistid
HK1043112A1 (zh) 取代的稠杂环γ-咔啉
MXPA03005438A (es) Pirioindoles substituidos como agonistas y antagonistas de serotonina.
ATE509929T1 (de) Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
EE200300301A (et) Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid
CA2354606A1 (fr) Derives d'azabicycloalkane et utilisations therapeutiques connexes
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses

Legal Events

Date Code Title Description
HB1A Correction of owner name or address